Thiazolidinediones increase bladder cancer risk while SGLT2 inhibitors show potential protective effects in Type 2 Diabetes
Diabetes medications show different links to bladder cancer risk
This meta-analysis of 85 studies evaluated the association between various antidiabetic medications and bladder cancer risk in patients with…
New data shows that while some diabetes medications may increase bladder cancer risk, others might offer a protective effect.
Targeted strategies like senolytics and PFKFB3 blockers show preclinical efficacy in chronic kidney disease
New research explores how cells drive chronic kidney disease
This narrative review explores the mechanisms of necroptotic tubular epithelial cell death and glycolytic reprogramming in chronic kidney di…
Scientists identified a self-amplifying cycle of cell death and aging that drives scarring in chronic kidney disease.
Diabetes mellitus acts as a context-dependent modifier of risk and phenotype in neurological disorders
Diabetes May Influence Risk and Progress of Neurological Disorders
This narrative review synthesizes evidence regarding the role of diabetes mellitus (DM) as a disease modifier across various neurological co…
New research suggests that diabetes can change how certain neurological conditions progress, potentially opening doors for new treatment opt…
Systematic review suggests modest risk reduction with SGLT2 inhibitors or ARNIs added to standard therapy in severe heart failure
Moderate evidence supports adding SGLT2 inhibitors to heart failure treatment
This systematic review and network meta-analysis evaluated adding SGLT2 inhibitors or angiotensin receptor-neprilysin inhibitors to neurohor…
A large analysis suggests adding SGLT2 inhibitors may lower risk of death or hospitalization for heart failure, though caution is advised.
Thiazolidinediones show lower hepatocellular carcinoma risk than DPP-4 inhibitors, GLP-1RAs, insulin, and sulfonylureas in this network meta-analysis
New analysis links diabetes drugs to liver outcomes in millions of patients
This network meta-analysis evaluated major adverse liver outcomes among 7124845 adults with type 2 diabetes using glucose-lowering drug clas…
A massive analysis of millions of patients found some diabetes medications linked to lower risks of serious liver events compared to others.
PRISMA Scoping Review Examines Food-Drug Interactions in Cardiovascular and Diabetic Medications
Meals May Not Matter for Most New Heart and Diabetes Pills
This PRISMA scoping review synthesized data from 36 publications regarding food-drug interactions in cardiovascular and diabetic medications…
Most new heart and diabetes pills work the same whether you take them with food or on an empty stomach, but a few still need timing.
Narrative review supports SGLT-2i use in cardiovascular-kidney-metabolic syndrome
New Treatment Shifts How We Fight Heart, Kidney, and Diabetes Damage
This narrative review summarizes evidence on SGLT-2 inhibitors for patients with stages 2–4 cardiovascular-kidney-metabolic syndrome.
Maria, 58, has type 2 diabetes and high blood pressure.
Meta-analysis of adjunctive SGLT2 inhibitors in type 1 diabetes shows mixed safety and efficacy signals
No More Bone Fear With New Diabetes Drug
This meta-analysis evaluated adjunctive SGLT2 inhibitor therapy in 6,731 patients with type 1 diabetes mellitus receiving insulin-based ther…
Many people with type 1 diabetes worry about their bones.
Meta-analysis of 13 trials finds SGLT2 inhibitors reduce heart failure hospitalization in myocardial infarction
New Drug Combo Lowers Heart Failure Risk After Heart Attack
This meta-analysis synthesizes data from 13 randomized controlled trials involving 22,238 patients with myocardial infarction.
Adding a specific diabetes medication to standard heart care may prevent future heart failure after a heart attack.
Review of heart failure medications and microbiome insights for individualized treatment strategies
Could gut bacteria help tailor heart failure treatment for better results?
This narrative review examines heart failure management involving digoxin, angiotensin receptor-neprilysin inhibitors, ACE inhibitors, ARBs…
Gut bacteria might help tailor heart failure treatments to work better for specific people by influencing how standard medicines affect the …
SGLT2i use linked to lower adherence and QOL in HF patients in cross-sectional MTAC study
Taking More Heart Pills May Actually Feel Better, Not Worse
A cross-sectional study of 78 heart failure patients in a Malaysian MTAC program found SGLT2i users had significantly lower adherence (p = 0…
Heart failure patients taking more heart medicines reported feeling better, not worse, in a new study from Malaysia.
GLP-1RA use shows sex-specific pancreatitis and hypotension risks in T2D second-line therapy study
Diabetes drugs work differently in women than men
A retrospective cohort study of 5.15 million adults with type 2 diabetes compared second-line therapies.
Diabetes drugs work differently for women than men, revealing distinct safety and effectiveness outcomes in a massive study of 5 million adu…
All sodium-glucose cotransporter 2 inhibitors Articles
- Thiazolidinediones increase bladder cancer risk while SGLT2 inhibitors show potential protective effects in Type 2 Diabetes
- Targeted strategies like senolytics and PFKFB3 blockers show preclinical efficacy in chronic kidney disease
- Diabetes mellitus acts as a context-dependent modifier of risk and phenotype in neurological disorders
- Systematic review suggests modest risk reduction with SGLT2 inhibitors or ARNIs added to standard therapy in severe heart failure
- Thiazolidinediones show lower hepatocellular carcinoma risk than DPP-4 inhibitors, GLP-1RAs, insulin, and sulfonylureas in this network meta-analysis
- PRISMA Scoping Review Examines Food-Drug Interactions in Cardiovascular and Diabetic Medications
- Narrative review supports SGLT-2i use in cardiovascular-kidney-metabolic syndrome
- Meta-analysis of adjunctive SGLT2 inhibitors in type 1 diabetes shows mixed safety and efficacy signals
- Meta-analysis of 13 trials finds SGLT2 inhibitors reduce heart failure hospitalization in myocardial infarction
- Review of heart failure medications and microbiome insights for individualized treatment strategies
- SGLT2i use linked to lower adherence and QOL in HF patients in cross-sectional MTAC study
- GLP-1RA use shows sex-specific pancreatitis and hypotension risks in T2D second-line therapy study
- Observational EHR study suggests GLP-1 RA may have lower risk than SGLT2i for HF outcomes